Regen Medicine Industry Seeks Increased Coverage, Quick FDA Reviews

Updated Story The regenerative medicine industry wants federal agencies and Congress to increase coverage and reimbursement for innovative gene therapies and to give FDA extra funding to expedite reviews of new gene therapy applications. The second iteration of the 21st Century Cures Act, Cures 2.0, could be one vehicle through which lawmakers tackle those key issues in 2020, stakeholders say. Stakeholders worry FDA doesn’t have the capacity to review and regulate the rapidly growing field of regenerative...